MUC1 and non-small cell lung carcinoma: Based on these results, a phase II/III trial enrolled 222 previously untreated stage IV NSCLC patients without EGFR mutation and with MUC1 expression ≥ 50% on tumor cells, to receive standard first-line chemotherapy with or without TG4010 vaccine [106].